Development of a real-time clinical decision support system upon the web mvc-based architecture for prostate cancer treatment

BackgroundA real-time clinical decision support system (RTCDSS) with interactive diagrams enables clinicians to instantly and efficiently track patients' clinical records (PCRs) and improve their quality of clinical care. We propose a RTCDSS to process online clinical informatics from multiple databases for clinical decision making in the treatment of prostate cancer based on Web Model-View-Controller (MVC) architecture, by which the system can easily be adapted to different diseases and applications.MethodsWe designed a framework upon the Web MVC-based architecture in which the reusable and extractable models can be conveniently adapted to other hospital information systems and which allows for efficient database integration. Then, we determined the clinical variables of the prostate cancer treatment based on participating clinicians' opinions and developed a computational model to determine the pretreatment parameters. Furthermore, the components of the RTCDSS integrated PCRs and decision factors for real-time analysis to provide evidence-based diagrams upon the clinician-oriented interface for visualization of treatment guidance and health risk assessment.ResultsThe resulting system can improve quality of clinical treatment by allowing clinicians to concurrently analyze and evaluate the clinical markers of prostate cancer patients with instantaneous clinical data and evidence-based diagrams which can automatically identify pretreatment parameters. Moreover, the proposed RTCDSS can aid interactions between patients and clinicians.ConclusionsOur proposed framework supports online clinical informatics, evaluates treatment risks, offers interactive guidance, and provides real-time reference for decision making in the treatment of prostate cancer. The developed clinician-oriented interface can assist clinicians in conveniently presenting evidence-based information to patients and can be readily adapted to an existing hospital information system and be easily applied in other chronic diseases.

[1]  J. Oesterling,et al.  Update on the appropriate staging evaluation for newly diagnosed prostate cancer. , 1997, The Journal of urology.

[2]  Gleason Df.  Classification of prostatic carcinomas. , 1966 .

[3]  J E Oesterling,et al.  PSA and staging of localized prostate cancer. , 1993, The Urologic clinics of North America.

[4]  M M Elhilali,et al.  Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. , 1994, Urology.

[5]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[6]  L. Walter,et al.  Cancer screening in elderly patients: a framework for individualized decision making. , 2001, JAMA.

[7]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[8]  A. Renshaw,et al.  Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .

[9]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[10]  N. Aaronson,et al.  Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. , 2002, JAMA.

[11]  G. Sensabaugh,et al.  Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. , 1978, Journal of forensic sciences.

[12]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[13]  R. Haynes,et al.  Effects of computer-based clinical decision support systems on physician performance and patient outcomes: a systematic review. , 1998, JAMA.

[14]  M. Ernstoff.  Clinical Aspects of Prostate Cancer , 2003 .

[15]  G. Murphy,et al.  Prostate antigen: A new potential marker for prostatic cancer , 1981, The Prostate.

[16]  David L. Dawson,et al.  The development of a web- and a print-based decision aid for prostate cancer screening , 2010, BMC Medical Informatics Decis. Mak..

[17]  Ethan Basch,et al.  Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship , 2010, BMC Medical Informatics Decis. Mak..

[18]  Michael W Kattan,et al.  Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[20]  R L Vessella,et al.  Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. , 1987, The Journal of urology.

[21]  et al.,et al.  A web-based library consult service for evidence-based medicine: Technical development , 2006, BMC Medical Informatics Decis. Mak..

[22]  Surajit Chaudhuri,et al.  An overview of data warehousing and OLAP technology , 1997, SGMD.

[23]  John T. Wei,et al.  The influence of prostate size on cancer detection. , 1995, Urology.

[24]  S B Malkowicz,et al.  Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. , 2001, The Journal of urology.

[25]  P. Walsh.  American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. , 2005, The Journal of urology.

[26]  M. Kattan,et al.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.

[27]  D. Chan,et al.  Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer , 2005, World Journal of Urology.

[28]  R. Haynes,et al.  Effects of Computer-Based Clinical Decision Support Systems on Physician Performance and Patient Outcomes , 1998 .

[29]  P. Shekelle,et al.  Systematic Review: The Evidence That Publishing Patient Care Performance Data Improves Quality of Care , 2008, Annals of Internal Medicine.

[30]  A. Wein,et al.  Campbell-Walsh Urology , 2011 .

[31]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[32]  P. Walsh.  Results of conservative management of clinically localized prostate cancer. , 1994, The Journal of urology.

[33]  R. Flanigan.  Diagnosis and staging of prostate cancer. , 1998, The Journal of urology.

[34]  Stuart Farber,et al.  Developing a Computerized Data Collection and Decision Support System for Cancer Pain Management , 2003, Computers, informatics, nursing : CIN.

[35]  D. Ornstein,et al.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.

[36]  Ralph Johnson,et al.  design patterns elements of reusable object oriented software , 2019 .

[37]  R. Haynes,et al.  Effects of Computer-based Clinical Decision Support Systems on Clinician Performance and Patient Outcome: A Critical Appraisal of Research , 1994, Annals of Internal Medicine.

[38]  Adam Wright,et al.  A four-phase model of the evolution of clinical decision support architectures , 2008, Int. J. Medical Informatics.

[39]  Jerome P. Richie,et al.  Diagnosis and Staging of Prostate Cancer , 2003 .

[40]  J E Fowler,et al.  Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer. , 1994, Surgery.

[41]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[42]  Angela Fagerlin,et al.  Evidence-based patient choice: a prostate cancer decision aid in plain language , 2005, BMC Medical Informatics Decis. Mak..